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Abstract
Gastroenteropancreatic neuroendocrine tumours (GEP NETs) are rare tumours that present many clinical features.
They secrete peptides and neuroamines that cause distinct clinical syndromes, including carcinoid syndrome. How-
ever, many are clinically silent until late presentation with mass effects.
In 2000 the WHO developed a new classification which gives a better description of the characteristics and biologi-
cal behaviour of the tumour.
Surgical resection is the treatment of first choice for a patient with a GEP NET. In metastatic disease multiple thera-
peutic approaches are possible. In these cases the goal is to improve quality of life and to extent survival.
GEP NETs express somatostatin receptors (SSTRs), which are bound by somatostatin (SST) or its synthetic analogues,
although the subtypes and number of SSTRs expressed is very variable.
Somatostatin analogues are used frequently to control hormone-related symptoms while their anti-neoplastic activ-
ity, even if it has not been widely studied and the regarding data are discordant, seems to result prevalently in
tumour stabilisation.
A few patients who fail to respond or cease to respond to standard SST analogues treatment seem to have a
response to higher doses of these drugs.
The use of higher doses of somatostatin analogues or the development of new subtype selective agonists and
chimaeric somatostatin analogues, or pan-somatostatin will probably improve the clinical management of these
patients.
This review provides an update on the use of somatostatin analogues in the management of GEP NETs and
discusses novel clinical strategies based on SSTR 2 gene transfer therapy.
Introduction
Gastroenteropancreatic neuroendocrine tumours (GEP
NETs) are an heterogeneous group of relatively rare
tumours, whose yearly incidence is 1.2-3.0 cases/100,000
inhabitants [1].
The database of the National Cancer Institute, Surveil-
lance Epidemiology and End Results (SEER), mirroring
the attention standards for US average patients, shows
that the age-related incidence of small intestine and
digestive tract carcinoids increased by 460% and 720%
respectively, within a period of 30 years [2]. GEP NETs
arise from local gastrointestinal stem totipotent cells,
rather than from the neural crest, as assumed at first [3].
According to the most recent histological classification of
tumour features - based on diameter and presence/
absence of local or distance metastases - developed by
the World Health Organization (WHO), tumours are
classified as:
a) well-differentiated neuroendocrine tumours; b) well-
differentiated neuroendocrine carcinomas;
c) poorly-differentiated neuroendocrine carcinomas; d)
mixed exocrine-endocrine carcinomas [4,5].
In most cases, they are single isolated forms, but they
can be multiple and part of familiar syndromes such as
MEN 1 syndrome, von Hippel-Lindau disease and neu-
rofibromatosis, type 1. These are mostly (well-differen-
tiated) tumours with relatively slow growth, even if * Correspondence: appetecchia@ifo.it
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differentiated carcinomas).
The clinical picture depends on the site of the primary
tumour and its ability to secrete neuroamines and pep-
tides at supra-physiological levels (functioning tumours),
able to cause a symptomatic response (clinical syn-
dromes). Among functioning tumours, major clinical
entities are: carcinoid syndrome, hypoglycaemic syn-
drome, Zollinger-Ellison syndrome, WDHA (Water
Diarrhea-Hypo-kaliemia-Achlorydria) syndrome, gluca-
gonoma syndrome.
However, 90% of GEP NETs do not produce biologi-
cally active hormones (non functioning tumours) and
therefore the diagnosis is often made too late, in pre-
sence of symptoms due to the mass effect and/or the
presence of metastases, mainly hepatic metastases [1].
In cases at advanced stages, with a diagnostic confir-
mation of metastasis, as well as in case of disease pro-
gression, the prognosis gets worse. In patients with
localised well differentiated neuroendocrine carcino-
mas, 5-year survival is 60-100%. With regional disease
or distant metastases 5-year survival is 40% and 29%,
respectively [6].
As a matter of fact, the median survival in these cases
is approximately 1 or 2 years.
Around 80% of GEP NETs express somatostatin
receptors (SSTRs), located on the cell membrane. There
are five different G-protein coupled receptor subtypes
(SSTRs 1-5) that are differently expressed in the various
types of tumour (Table 1 and 2). Tumours expressing
SSTRs often contain one or more receptor subtypes. In
addition, recent studies have shown that such receptors
a r ep r e f e r a b l ye x p r e s s e di nwell-differentiated forms,
that some advanced tumours loose particular receptor
subtypes while keeping others [7,8], that SSTR subtypes
can form homo/heterodimers at the membrane level, to
develop new receptors with different functional features
[9], and that this receptor “association” m a yb ei n d u c e d
by addition of either dopamine or somatostatin.
In a study examining 81 functioning and non-func-
tioning GEP NETs the large parte of the tumours
expressed SSTRs 1, 2, 3 and 5, while SSTR 4 was
detected only in a small minority [10].
Somatostatin receptors have been extensively mapped
in different pancreatic tumours by means of autoradio-
graphy, reverse-transcription polymerase chain reaction,
in situ hybridization and immunohistochemistry; SSTRs
1, 2, 3 and 5 are usually expressed in pancreatic NETS.
Pancreatic insulinomas had heterogeneous SSTRs
expression while 100% of somatostatinomas expressed
SSTR 5 and 100% gastrinomas and glucagonomas
expressed SSTR 2 [11].
Somatostatin (SST) is a natural peptide hormone
secreted in various parts of the human body, including
the digestive tract, able to inhibit the release of numer-
ous endocrine hormones, including insulin, glucagon,
and gastrin. The biological effects of somatostatin are
mediated through its specific receptors (SSTR 1-5) with
a high degree of sequence similarity (39-57%) and which
have been cloned in the early 1990s. They all bind nat-
ural peptides, somatostatin 14, somatostatin 28 and cor-
tistatin with similar high affinity (nM range). However,
endogenous somatostatin short half-life in circulation
(1-3 min), makes it difficult to use it continuously and
has resulted in the development of synthetic analogues.
By the early 1980s a number of short synthetic analo-
gues of somatostatin including SMS201-995 (octreotide),
RC-160 (vapreotide), BIM 23014 (lanreotide), and MK
678 (Seglitide) were developed.
These cyclic octapeptides are more resistant to pepti-
dases and their half-lives and hence their biological
activities are substantially longer than native somatosta-
tin (1.5-2 h vs 1-2 min) [12].
The development of a depot formulation of octreotide,
Sandostatin LAR (Novartis) (long-acting repeatable),
administered up to 30-60 mg once every 4 weeks has to a
large extent eliminated the need for daily injections. Lan-
reotide (Somatuline; Ipsen, Slough, UK), a long-acting
somatostatin analogue administered every 10-14 days, has
a similar efficacy to octreotide in the treatment of carci-
noid tumors, but its formulation is easier and more
Table 1 Somatostatin receptors
a in neuroendocrine
gastroenteropancreatic tumours [%]
SSTR1 SSTR2 SSTR3 SSTR4 SSTR5
All 68 86 46 93 57
Insulinoma 33 100
b 33 100 67
Gastrinoma 33 50 17 83 50
Glucagonoma 67 100 67 67 67
VIPoma 100 100 100 100 100
N-F 80 100 40 100 60
VIP, vasoactive intestinal polypeptide; N-F, Non functioning;
aUsing receptor
subtype antibodies;
bMalignant insulinoma
[Modified from Oberg K, Annals of Oncology, 2004]
Table 2 Somatostatin receptor subtypes mRNA in
neuroendocrine tumours
Tumor SSTR1 SSTR2 SSTR3 SSTR4 SSTR5
Gastrinoma 79%
a 93% 36% 61% 93%
Insulinoma 76% 81% 38% 58% 57%
N-F 58% 88% 42% 48% 50%
Carcinoid
(gut)
76% 80% 43% 68% 77%
SST, somatostatin receptor; N-F, Non functioning;
a Indicates the percentage of
positive tumours for each sst. mRNA expression may overestimate the number
of receptors present, depending on the technique used [PR-polymerase chain
reaction, Northern blot, in-situ hybridization].
[Data from Plöckinger U. Biotherapy. Best Practice & Research Clinical
Endocrinology & Metabolism 2007; Vol. 21, No. 1, pp. 145-162]
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depot preparation of lanreotide, Lanreotide Autogel
(Ipsen), is administered subcutaneously up to 120 mg
once a month [14].
Native SST and its synthetic analogues show different
affinity for the five specific receptor subtypes [9,10,15].
Native SST binds all the five receptor subtypes (SSTRs
1-5). The effects of the SST analogues are mediated by
the interaction with SSTR 2 and 5 receptors while the
new somatostatin analogue, pasireotide (SOM 230),
shows higher binding capacity towards SSTRs 1, 2, 3
and 5 with no agonist activity at the type 4 receptor
[15] (Table 3). The different receptor subtypes binding
affinities seem to result in different biological and clini-
cal activities. Octreotide is, for instance, 45 times more
potent in inhibiting growth hormone (GH) secretion
and 11 times more potent in inhibiting glucagon secre-
tion than native SST [10].
The symptomatic and biochemical effects
of SST analogues
The initial treatment of GEP NETs is, where possible,
always an aggressive surgical approach, aimed at obtain-
ing a curative tumour ablation, even in the presence of
metastatic disease. However, in patients with functioning
or metastatic tumours, the treatment goal is to improve
their quality of life, while monitoring or alleviating the
tumour-associated symptoms and increasing survival.
Recently, the diagnostic and therapeutic approach of
GEP NETs has considerably improved, mainly due to
better imaging techniques (CT, MRI, PET) and somatos-
tatin analogue-based imaging methods, as well as recep-
tor subtype characterisation and the introduction of
long-acting somatostatin analogues.
Somatostatin receptor scintigraphy (SRS, OctreoScan®),
(e.g.
111In-pentetreotide) can visualise in vivo tumours
and metastases that express the somatostatin receptor
subtypes 2, 3 or 5 [16] except for metastatic insulino-
mas, of which only 50% express SSTR 2. Imaging by
SRS is not dependent on endocrine function of a NET
but is determined by the tumour’s endowment of
SSTRs. This somatostatin analogue-based imaging
method may help to decide which patients are suitable
for treatment with somatostatin analogues (octreotide or
lanreotide), or for tumour-targeted radioactive therapy
with radiolabelled somatostatin analogues [13,17-22]. Its
overall is high, ranging from 86% to 95% for gut carci-
noid tumours to 75-100% for pancreatic endocrine
tumours [21,22]. The uptake of radiolabeled octreotide
is also predictive of clinical response to therapy with
somatostatin analogues.
Since 1980, SST analogues have been used to sympto-
matically control GEP NETs, especially carcinoids and
VIPomas [11,13]. Usually, the treatment with long acting
preparations of SST analogues consists in an intramus-
cular injection (i.m.) every 2 or 4 weeks (octreotide
long-lasting, 10-30 mg, LAR; lanreotide long-lasting 60-
120 mg LA). In the course of the first two months, addi-
tional subcutaneous (s.c.) administrations of short half-
life octreotide may be required before achieving such
properly stable blood levels of the long half-life synthetic
analogue, as to allow adequate symptom control. Their
efficacy in the control of symptoms is well-documented
[2,12,13], even if patients with islet cell tumour often
show a transient (median time 2.5 months) and non-sig-
nificant response. These are safe and well-tolerated
drugs, in both long- and short-term treatments [23-27].
However, after 9-12 months, drug resistance often
spreads and patients may show symptom recrudescence.
In such cases, the approach proposed was to continue
the treatment, by increasing the analogue dosage (for
octreotide with gradual increments of 10 mg every 28
days up to 60 mg every 28 days) or, by shortening the
administration range by a week [28], if the symptomato-
l o g i ce s c a p eo c c u r si nt h ew e e kb e f o r et h en e x td r u g
injection.A randomised double-blind trial compared
long- acting octreotide LAR at 10, 20, and 30 mg every
4 weeks with open-label short-acting octreotide every 8
h for the treatment of carcinoid syndrome. It showed
t h a tt h ee f f i c a c yo fs h o r t - a c t i n go c t r e o t i d ea n do ft h e
long-acting octreotide-LAR was the same once circulat-
ing octreotide steady-state concentrations were achieved
[29].
O’Toole et al in a multicentre study on 33 patients
with the carcinoid syndrome comparing the treatment
with lanreotide (30 mg i.m. every 10 days) versus
octreotide (200 μg s.c. twice or thrice daily) founded no
significant differences in controlling symptoms; 53.8%
and 45.4%, respectively, of the patients treated with lan-
reotide referred disappearance or improvement in
flushes and diarrhoea, while these symptoms were
observed in 68% and 50%, respectively, of patients on
octreotide. Lanreotide and octreotide may also signifi-
cantly lower the levels of urinary 5-hydroxyindoleacetic
acid (5-HIAA), the catabolite of serotonin [30].
Table 3 Somatostatin receptor subtype-binding affinity
of somatostatin analogues
Receptor subtype affinity [IC50, nM]
Compound SSTR1 SSTR2 SSTR3 SSTR4 SSTR5
SMS-14 2.26 0.23 1.43 1.77 0.88
SMS-28 1.85 0.31 1.3 ND 0.4
Octreotide 1140 0.56 34 7030 7
Lanreotide 2330 0.75 107 2100 5.2
Pasireotide 9.3 1 1.5 >100 0.16
SMS, Somatostatin; ND, not determined.
[Data from Grozinsky-Glasberg S., Endocrine-Related Cancer 2008 Sep;15
[3]:701-20].
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the 28-day aqueous prolonged release formulation of
lanreotide in 75 patients in a 6-month dose-titration
study. Thirty percent of patients showed a biochemical
response and 75% and 80% of patients reported resolu-
tion of diarrhea and flushing, respectively, which is com-
parable with the reported effects of other lanreotide
preparations. The median decrease in levels of urinary
5-HIAA and serum chromogranin A was 24% and 38%,
respectively [31].
An interim analysis of a phase II trial of SOM230 in 21
patients with metastatic carcinoid tumours whose symp-
toms (diarrhea and flushing) were refractory/resistant to
octreotide LAR showed symptom relief in 33% [32].
Approximately 10-15% of patients with midgut carci-
noids suffer from watery diarrhoea, flushing, right-sided
heart failure and bronchial constriction (carcinoid syn-
drome), due to the tumour hypersecretion of a variety
of endocrine substances, the most frequent of which are
serotonin (5-hydroxytryptamine) and the tachykinins
[33,34], and therefore somatostatin analogues are impor-
tant palliative tools for these patients. In insulinoma it
has been noted that octreotide treatment may make
hypoglycemia worse in those patients lacking SSTRs 2
and 5, and, as glucagon secretion is also inhibited,
patients have to be observed closely at the beginning of
therapy to prevent severe hypoglycemia due to the
reduced glucagon-dependent counter-regulation [35].
Hence, this treatment has to be started in a hospital set-
ting, and should be reserved for only the minority of
insulinoma patients with positive imaging on SRS.
Vezzosi et al recently assessed that octreotide was
effective in the control of hypoglycaemia in more than
50% of the insulinoma patients. The treatment was
effective in all SSTR 2 positive patients and in a few
SSTR 2 negative ones, while no relation between treat-
ment effectiveness and the expression of SSTR 5 was
observed [36]. These results are in concordance with
other case reports and smaller series of insulinoma
patients reported in the literature [37-41].
In glucagonoma patients somatostatin analogue treat-
ment is indicated for alleviating the symptoms related to
the characteristic skin rash (necrolytic migratory
erythema) or diarrhoea [42-46].
In somatostatinomas symptoms are due to somatosta-
tin hypersecretion (hyperglycaemia, cholelithiasis, diar-
rhoea and steatorrhoea, hypochlorhydria) or to the mass
effect [47]. Although it seems a paradox to treat patients
with symptoms related to elevated SST levels with a
somatostatinoma, in 1998 Angeletti et al showed that
octreotide treatment was effective in reducing plasma
levels of somatostatin and improving the related symp-
toms in three patients with metastatic somatostatinomas
[48].
Recently, have been described nine cases of VIP-oma
in which octreotide was very successful as adjuvant ther-
apy for symptoms control and for reducing the serum
elevated VIP levels improving the diarrhoea and the
electrolyte imbalance [49-51].
The anti tumour effects of SST analogues
The antineoplastic activity of somatostatin analogues has
been demonstrated in several experimental models in
vivo and in vitro [52-57]. However, there is still little
known regarding the antiproliferative role of SSA in
GEP NETs, although increasing data suggest that such
analogues can be tumouristatic, at least in some circum-
stances [58].
The antineoplastic action of SST analogues depends
on the kind of tumour and the receptor subtypes they
are bound to, and occurs through direct and indirect
mechanisms. While direct activities are mediated by spe-
cific membrane receptors and include antimytotic and
apoptotic effects, indirect effects do not depend on the
receptor bonging and encompass the growth factor inhi-
bition, antiangiogenic and immuno-modulating activ-
ities. As a matter of fact, SST analogues are able to
inhibit the growth of Swarn chondrosarcoma, used as
experimental model of SSTR free tumour [59].
The mitosis inhibition is mediated by SSTRs 2 and 5
and results in the cell cycle arrest [55]. The loss of the
SSTR 2 expression in some human adenocarcinomas
seems to be responsible for loosing the regulation of cell
proliferation [8]. The loss of SSTR 2 may consequently
promote tumour growth and make it clear the therapeu-
tic inefficacy of SST analogues in such kind of neoplasia.
Apoptosis [programmed cell death] seems to be induced
by two different processes: interaction with the SSTR 3
[53] and inhibition of the Insulin-like Growth Factor
I (IGF I), potent antiapoptotic hormone [60]. The pro-
apoptotic activity of SST analogues seems to have clini-
cal relevance, as shown by the interesting findings
published by Eriksson et al. that reported an increase in
apoptosis in bioptic samples of tissues by patients with
GEP NETs, after the treatment with SST analogues at
high doses. It followed that apoptosis is related to the
biochemical response and the disease stabilisation (70%
of cases) [61,62].
However, Faiss et al. observed an overall response rate
(ORR) of 6.7%, comparable to that recorded at conven-
tional doses [63], in 24 patients with GEP NETs treated
with high doses of lanreotide (15 mg/day).
The indirect antiproliferative efficacy of SST analogues
is shown by an antiangiogenic mechanism. Angiogenesis,
that is the growth of new blood vessels, is essential for
tumour growth and metastasis spread. Consequently,
the growth can be actually controlled by reducing the
vascularisation of the neoplastic tissue. In experimental
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which is probably mediated by the inhibition of the Vas-
cular Endothelial Growth Factor (VEGF) [64-66]. The
response to the treatment with octreotide would result
in a significant reduction in VEGF levels compared to
the baseline, since it is related to patients’ survival [66].
It was observed that standard endothelial cells do not
express the SSTR 2 that is present on the contrary,
when they proliferate in order to form blood vessels.
This could represent further opportunity to treat
patients with octreotide that is able to recognise and inhi-
bit new vessel formation both alone and with other
drugs, thanks to its high affinity with such receptor
(Table 3). Immunomodulation is another indirect
mechanism of action of SST analogues. Preliminary evi-
dence suggests that they stimulate the production of
immune system components with antitumour effect,
such as natural-killer cells [67,68], even if up to now it is
not clear whether this can be clinically significant thus
helping the antitumour efficacy of SST analogues. Few
data exists on the functions mediated by the SSTR 4.
However, no unanimity exists about the SST analogue
ability to control (i.e. to slow) the tumour progression.
In vitro studies reported that the response of different
cell lines to the octreotide exposition produces a bipha-
sic dose-response curve [69,70]. Consequently, overdose
or underdose of SST analogues may result in a subopti-
mal antineoplastic activity. Nevertheless, the negative
results of some clinical studies in terms of tumour
response could be due to the administration of too low
doses to achieve receptor optimal saturation. After all,
in other studies that used octreotide doses higher than 8
mg/day and lanreotide doses higher than 10 mg/day
[71], no improvement of the SST analogue antitumour
effect was observed. No study on the tumour response
monitored plasma levels of an SST analogue up to now,
in order to assess that optimal drug therapeutic levels
are reached but not exceeded [72]. Clonflicting results
have given with regard to tumour regression. Tumour
shrinkage was demonstrated in less than 10% of the
patients. However, a stabilisation of tumour growth
occurs in up to 50% of the patients with neuroendocrine
tumours of various locations. Stable disease was
observed in 37-45% of the patients with documented
tumour progression before SSA therapy (Table 4). The
median duration of stabilisation was 26.5 months
[26,73-76]. In a study on a select group of patients with
progressive disease, in the 47% of cases was demon-
strated a stable disease when treated with a high dose of
lanreotide (3-5 g/day) [77]. This result has been con-
firmed in patients with advanced midgut carcinoids,
who had a stabilisation of the disease for 6-24 months
in the 75% of cases [78]. One patient with a pancreatic
primary tumour, and distant extrahepatic metastases,
showed a poor response to treatment in multivariate
analysis. Age, size of the primary tumour, and Ki67 did
not influence the response rate to SSA therapy [76]. A
stabilisation of the disease was maintain throughout
long-term follow-up in patients who achieve it after 6
months of treatment; these patients live longer than
those unresponsive to therapy [76,79].
Very recently Rinke et al performed for the first time
a placebo-controlled, double-blind, phase IIIB study in
85 patients with well-differentiated metastatic midgut
NETs using octreotide LAR 30 mg intramuscularly in
monthly intervals. Median time to tumour progression
in the octreotide LAR and placebo groups was 14.3 and
6 months, respectively. After 6 months of treatment,
stable disease was observed in 66.7% of patients in the
octreotide LAR group and 37.2% of patients in the pla-
cebo group. Functionally active and inactive tumours
responded similarly. The most favorable effect was
observed in patients with low hepatic tumour load and
resected primary tumour. Octreotide LAR significantly
Table 4 Antiproliferative effect of somatostatin analogues in patients with progressive disease
SSA Dosage N CR PR SD PD References
Lanreotide 3000 mg/day 22 0 1 7 14 [97]
Lanreotide 30 mg/2 weeks 35 0 1 20 14 [90]
Octreotide 600 and 1500 mg/day 52 0 0 19 33 [74]
Octreotide 1500 and 3000 mg/day 58 0 2 27 29 [26]
Lanreotide 15000 mg/day 24 1 1 11 11 [97]
Octreotide 600 mg/day 10 0 0 5 5 [73]
Octreotide median dose of 250 μg three times daily 34 0 1 17 0 [75]
Octreotide LAR 30/
Lanreotide SR
60 mg/28 days 31 0 0 14 4 [76]
Total 256 1 6 115 105
Percentage (%) 0.3 2 45 41
SSA, somatostatina analogues; CR, complete remission; PR, partial remission; SD, stable disease; PD, progressive disease.
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placebo in patients with functionally active and inactive
metastatic midgut NETs [80].
Midgut carcinoids express somatostatin receptors in
80 to 100% of cases. SSTR 2 is the most frequently
expressed [34]. The antiproliferative effect of somatosta-
tin analogues on the growth of the midgut carcinoids is
unknown. A partial or complete responses were
observed in less than 10% of the patients, while stabilisa-
tion of tumour growth was noticed in 24-57% of the
patients [6].
Few data are available regarding the role of somatosta-
tin analogues in the treatment of gastrinomas. In a study
of 15 malignant gastrinoma, in about 50% of these
patients, octreotide had an antiproliferative effect,
including one patient with tumour regression and seven
patients with tumour stabilisation [mean period 25
months] patients [81].
The long-acting somatostatin analogue octreotide-LAR
was administered in a patient with multiple type A gas-
tric carcinoids for a period of 9 months with a normali-
sation of serum gastrin levels and permanent
disappearance of the tumour [82]. Fykse et al. treated
five patients with hypergastrinaemia and gastric carci-
noids for a period of 1 year with monthly injections of
octreotide-LAR with a significant reduction in tumour
load, ECL cell density and normalisation of circulating
chromogranin A levels, indicating a possible direct anti-
proliferative effect of the treatment [83]. These results
suggest that the somatostatin analogues could have an
important antiproliferative effect. However, data on the
effect of somatostatin analogues on tumour growth in
patients with gastric carcinoids type C or poorly differ-
entiated endocrine carcinomas are scanty. In poorly dif-
ferentiated gastric carcinomas, treatment with
somatostatin analogs is not considered.
As surgical excision is the definitive treatment of insu-
linoma, there are few contrasting data in the literature
regarding the inhibitory effect of the somatostatin analo-
gues on the growth of these tumours. Grozinsky-Glas-
berg et al have conducted a study regarding the effects
of somatostatin analogues on cell proliferation in the
rat-derived insulinoma cell line (INS1). Their prelimin-
ary data show that octreotide has a significant inhibitory
effect on cell proliferation, as assessed by cell counting
and MTS assay, and on phosphorylation states of a
number of proteins in the PI3K/Akt/mTOR pathway
[84,85]. In his work, Vezzosi founded that despite
achieving hypoglycaemic control, insulinoma size
remained unchanged or increased moderately despite
normal blood glucose levels, concluding that somatosta-
tin analogues, as medical treatment is not sufficient to
prevent tumour growth in patients with malignant insu-
linomas [36].
In 2006, Romeo et al reported a complete clinical
remission with regression of the metastatic lesions in
the liver after one year in a patient affected by meta-
static insulinoma with severe hypoglycaemia treated
with octreotide LAR [85].A more controversial area con-
cerns the treatment of patients with non-functioning
endocrine tumours of the pancreas as few studies have
been published in these patients. The prospective Ger-
man Sandostatin multicentre phase II trial investigated
the effects of octreotide for one year on tumour growth
in 103 patients and included 15 patients with diagnosed
non-functional pancreatic tumours [74]. Only 3 out of
these 15 patients had a stable disease, in 8 patients a
tumour progression occurred while the outcome of the
remaining four patients was not clear. As previously
said, the SST analogue efficacy depends on the tumour
receptor expression patterns, but these are rarely
assessed, even if there is evidence of better results on
survival obtained with selective treatments. An antiproli-
ferative effect was achieved on hepatic metastatic cells
in a patient with a carcinoid tumour, selected for the
treatment with SST analogues after the immunohisto-
chemical identification of the SSTR 1, 2 and 5 subtypes
expression on the neoplastic cell surface [86]. A com-
plete clinical remission with regression of the metastatic
lesions in the liver after one year of treatment was
observed in a patient affected by metastatic insulinoma
with severe hypoglycaemia treated with octreotide LAR
expressing at immunohistochemical analysis of tissue
specimens a strong membrane immunoreactivity for
SSTR 2 in both the primary nodule and the metastases
[85]. However, another study showed neither an anti-
neoplastic effect nor an increase in survival percentage
of treated patients [87].
It has been reported that in glucagonoma patients
there are no data available on their SSTR expression
patterns [45]. In 2006 we demonstrated, for the first
time, a scattered immunopositivity for somatostatin
receptors in a case of malignant glucagonoma.We had
access to polyclonal antibodies specifically targeted
against SSTR5 and SSTR2 and we were therefore able
to localise these two receptors in our histological sec-
tions. The immunopositivity was detected for both
receptor subtypes in the membrane and in the cyto-
plasm of glucagonoma cells. We then treated our patient
with a combination therapy consisting of the somatosta-
tin analogue octreotide and interferon-a.T h ep a t i e n t
had a complete resolution of skin rash, normalisation of
plasma glucagon, chromogranin A and neuron specific
enolase levels, and metastatic disease stabilisation. The
patient’s quality of life significantly improved, and she
was alive 40 months after debulking surgery [46].
In conclusion, in many cases authors did not stratify
patients in treatment arms, according to the histological
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sion. Consequently, most of them were likely not to be
treated with the optimal drug required to achieve appro-
priate receptor saturation.
The effects of higher than usual dose of SST
analogues
It was suggested that higher than usual dose of somatos-
tatin analogues treatments (>3,000 μg/day) may promote
the anti-proliferative effect, especially in those patients
responding to standard doses [2,15,16,78,88,89]. An
high-dose treatment with lanreotide (up to 12 mg/day)
produced tumour size reduction in 5% and stabilisation
in 70% of the 19 patients. In responding patients was
observed an induction of apoptosis in the tumours, a
phenomenon not seen with regular doses of somatosta-
tin analogs, but often produced by chemotherapeutic
agents [62]. Subcutaneously injections of 5 mg lanreo-
tide three times a day for a period of 1 year produced
one complete and one partial remission in 30 patients
with functional midgut NETs; stable disease in 11
patients (36%) and progression of the disease after 3-12
months of treatment in 11 patients [63]. The treatment
with high-dose somatostatin analogues induced apopto-
sis in neuroendocrine tumours, while this was not found
during treatment with low-dose somatostatin, in a study
where biopsy specimens were taken before and during
somatostatin analogue treatment [61].
In a highly select group of patients with progressive
disease, 47% of the patients demonstrated at least stable
disease when treated with a high dose of lanreotide
(3-5 g/day) [77].
High-dose formula of octreotide has been recently
reported to stabilize hormone production and tumour
growth in 75% of patients with advanced midgut carci-
noid tumours and progressive disease with stabilisation
for 6-24 months, [78].
These effects may be attributable to SSTR 2 which is
the most frequently expressed subtype and/or SSTR 5, 1
and 3 which are also expressed [90,91].
Data from a study with ultra-high dose octreotide
pamoate (Onco-LAR; Novartis) at 160 mg intramuscu-
larly every 2 weeks for 2 months followed by the same
dose once monthly, appear to show some promise.
Tumour size stabilisation was obtained in 12 patients, a
biochemical responses in 9 patients and/or stability in
11. No significant tumour reduction was noted. At 6
months, the median plasma concentrations of octreotide
were 25-100 times higher than those obtained by using
octreotide LAR at regular doses. A significant inhibition
of angiogenesis was also showed through the down-reg-
ulation of proliferative factors such as vascular endothe-
lial growth factor (VEGF) and fibroblast growth factor
[12]. The highest response rates were reported using
octreotide in doses greater than 30 mg/day or lanreotide
in doses greater than 5 mg/day (and up to 15 mg/day)
[63].
Tomassetti et al. have reported that after one-year
therapy, the tumour completely disappeared in three
patients suffering from gastric carcinoid, two of whom
were treated with lanreotide 30 mg i.m. every 10 days
[92].
Cirillo in his retrospective study on 165 patients with
digestive NETs confirmed that somatostatin analogs can
have a role in the treatment of digestive neuroendocrine
tumors with low grades of malignancy, a low cellular
proliferation index and a high specific receptorial den-
sity in vivo, showing a SD ranging from 60 to 66%.
Moreover, an increase of the dosage of somatostatin
analogs seems to have a better control both of the dis-
ease progression and the chronic refractory diarrhea
[24].
Somatostatin analogues and interferon
The combination of SSAs and interferon (IFN) has been
used in an effort to enhance the antiproliferative effect
of interferon therapy, to add the positive effect of SSAs
on hypersecretory syndromes, and to reduce the dose of
IFN and thus the number of IFN-related side-effects.
Whether somatostatin analogues and IFN show a
synergistic effect on tumour growth and in carcinoid
syndrome symptom management is matter of debate.
The combination therapy with somatostatin analogues
and IFN is in fact limited by the small number of trials,
with variable results.
This combination seems of benefit in patients where
the usual octreotide treatment failed to achieve a bio-
chemical and symptomatic control [93].
This combination therapy leaded to a significantly
lower risk of progressive disease compared with soma-
tostatin analogues alone, and had a higher median survi-
val (51 vs 35 months) [94]. An anti-proliferative effect of
the addition of a-interferon to octreotide was showed in
a subgroup of patients with advanced metastatic disease
unresponsive to octreotide monotherapy, and prolonged
survival was reported in the responder group [95]. How-
ever, most published data do not support a major effect
of interferons over and above that of somatostatin ana-
logues. In a prospective multicenter study on the effect
of combination therapy, Faiss et al showed no advantage
on either biochemical or antiproliferative results, while
the number of side-effects increased [96].
Novel somatostatin analogues
Recently the universal or “pan-receptor” somatostatin
ligand pasireotide (SOM230) has been developed, which
possess high affinity binding to SSTs 2, 3 and 5, moder-
ate affinity for SSTR 1. Its receptor binding profile is
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octreotide. In a multicentre study on metastatic carci-
noid tumours patients whose symptoms (diarrhoea and
flushing) were refractory to octreotide-LAR, pasireotide
at dosages between 450 μg and 1200 μg twice a day
effectively controlled symptoms in 33% of these patients
[97]. These results support the hypothesis that pasireo-
tide may have potential in the treatment of these
tumours. Subtypes of somatostatin and dopamine recep-
tors may form homo- and hetero-dimers at the mem-
brane level, and this receptor “association” may be
induced by addition of either dopamine or somatostatin.
Recently, subtype selective analogues and antagonists, as
well as bi-specific and hybrid somatostatin/dopamine
compounds, binding to SSTR 2, SSTR 5 and dopamine
2 receptors have been developed [98]. Their effects have
been studied in several animal and human cell lines, and
also in primary cultures from human tumours. Regard-
ing their activity the literature is scanty. Further studies
are needed to understand their complex and heteroge-
neous effects. Chimeric somatostatin-dopamine com-
pounds (dopastatins) with high affinity for SSTRs 2 and
D2 receptor (D2R) (BIM-23A387) or to SSTRs 2, 5 and
D2R (BIM-23A760) have been showed to inhibit cell
proliferation of the non-small-cell lung cancer cell line
Calu-6, which expresses SSTRs 2, 5 and D2R with
higher potency and efficacy than SSTR 2 and D2R ana-
logues [99]. BIM23A760 can also inhibit ECL cell prolif-
eration with similar potency but with higher efficacy
than lanreotide and D2R analogue [9]. The enhanced
potency/efficacy of BIM-23A387 and BIM-23A760 may
in part be due to the high affinity of these compounds
for SSTR 2. However, SSTR 2 can heterodimerize with
SSTR 5, and SSTRs 2 and 5 can form heterodimers with
D2R which can alter receptor ligand binding affinity
and/or signaling and/or receptor trafficking [100-102].
The presence of SSTRs in a higher density in NETs and
their ability to form a receptor-ligand complex, can per-
mit the internalisation and the accumulation of radio-
pharmaceutical inside the tumour [103].
A novel targeted cytotoxic somatostatin octapeptide
conjugates such as RC-121 and RC-160 coupled to dox-
orubicin or its superactive derivative, 2-pyrrolino-DOX
(AN-201) was synthesised from Schally and coworkers
[56]. AN-238, which contains AN-201 linked to carrier
RC-121, has been demonstrated to suppress the growth
of Hs746T and NCI-N87 human gastric cancers, which
display a high concentration of SSTRs 2 and 5 and
seems to target vascular SSTRs in a xenograft tumour
model derived from SSTRs negative tumour cells [56].
Another cytotoxic somatostatin analog termed JF-10-
81 has been synthesized by Coy and coworkers. This
somatostatin analogue, conjugated to camptothecin,
inhibits prostate cancer PC-3 cell invasion through a
signaling pathway involving PI3K, integrin aVb3/aVb5
and matrix metalloproteinases 2 and 9 and exhibited
anti-invasive and anti-angiogenic properties in vivo
[103].
SSTRs are able to form a receptor-ligand complex,
that permit the internalisation and the accumulation of
the radiopharmaceutical inside the tumour.
Peptide-receptor radionuclide therapy (PRRT) repre-
sents an important treatment strategy for tumours that
express adequate densities of SSTRs and has proven to
be safe and effective.
It was initially performed using indium-111 [19,104].
Recently, the development of somatostatin peptides with
higher receptor affinity conjugated with radio-metal
labelling chelators, such as DOTA (1,4,7,10-tetrazacyclo-
dodecane-N, N’, N”, N"’-tetraacetic acid), which may be
allow stable labelling with gallium, yttrium or lutetium,
changing the affinity profile for particular subtypes of
SSTRs can permit new therapeutic options [105]. Wald-
herr et al evaluated the tumour response to targeted
irradiation with the radiolabelled somatostatin analogue
90Y-DOTATOC in 41 patients with GEP NET and
bronchial tumours. They reported an overall response
rate of 24%. For endocrine pancreatic tumours it was
36%. A complete remission was found in 2%, a partial
remission (PR) in 22%, a minor response in 12%, stable
disease in 49% and progressive disease in 15% of
patients. The treatment was well tolerated and there
was a significant reduction of symptoms and the 2-year
survival time was 76 ± 16% [106].
177Lu DOTATATE [177Lu]DOTA-Tyr(3)-octreotate,
a selective analogue of SSTRs 2. In spite of its favour-
able affinity profile, at its maximum tolerated dose, it is
limited by toxic effects on the kidney and bone marrow.
Nevertheless, the results seem encouraging compared
with historical therapeutic data [107].
Kwekkeboom et al obtained promising results using
177Lu DOTATATE [177Lu]DOTA-Tyr(3)-octreotate in
131 patients with NETs. A complete remission was
observed in 2% of patients, a partial remission in 26%, a
minor response in 19%, stable disease in 35%, and pro-
gressive disease in 18% of patients. Higher remission
rates were positively correlated with high uptake on pre-
therapy SSTRs imaging, whereas progressive disease was
significantly more frequent in patients with extensive
disease. Median time to progression was more than 36
months [19].
The combination of
90Y- and
177Lu-labeled analogues
[108] seems to have had superior antitumour effects
when compared with either
90Y- or
177Lu-analogue in
animals presenting with tumours of various sizes. It has
been reported that
177 L u t e t i u mm a yb em o r ee f f e c t i v e
f o rs m a l l e rt u m o u r sw h e r e a s
90yttrium may be more
effective for larger tumours [109,110].
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has been considered as an opportunity to use radiola-
beled somatostatin analogues, in order to achieve a cyto-
toxic effect [
111In-labelled analogues,
90yttrium or
177lutetium] [111].
Novel strategies based on SSTRs 2 receptor gene
transfer to target tumour growth and angiogenesis
represents a new advance in the treatment of unresect-
able pancreatic tumours.
Buscail et al initially demonstrated that in human pan-
creatic adenocarcinoma SSTR 2 expression was specifi-
cally los[8].
Once gene defect corrected, cell growth as well as
tumorigenicity, were significantly reduced in the absence
of exogenous ligand [112]. The synthesis and secretion
of the natural ligand somatostatin-14 by sst2-transfected
cells was responsible for an autocrine/paracrine inhibi-
tory loop [57].
Several study conducted on pancreatic adenocarci-
noma animal models demonstrated that intratumoural
SSTR 2 gene transfer (using polyethylenimine synthetic
vector) inhibited intratumoural production of somatos-
tatin that was critical for the SSTR 2 antitumoral effect.
Primary tumour growth and angiogenesis were highly
decreased and associated with a reduction in microves-
sel density, inhibition of intratumoural production of
VEGF and up-regulation of antiangiogenic SSTR 3
receptor expression in peripheral tumour vessels
[32,113,114].
Conclusion
Neuroendocrine tumors of the gastroenteropancreatic
(GEP NETs) system comprise a rare group of malignant
neoplasms. The somatostatin analogues have been
shown to be very useful for symptomatic and biochem-
ical improvement in patients with these tumours while
preclinical and clinical studies provide conflicting results
on their antitumour effects. The mechanisms of these
effects are unknown, but probably are in part due to
direct effects on proliferative signalling pathways, activa-
tion of apoptosis, and effects on angiogenesis.
Biological response to somatostatin analogs depends
on distribution and level of expression of SSTRs sub-
types in tumours, and the expression of selective soma-
tostatin receptor-signaling pathway molecules.
The high density of SSTR2 in endocrine tumours
explains the use of SSTR 2 specific analogues in the diag-
nosis and treatment of these tumours. However, the role
of SSTR1,3 and 5 appears to be of increasing interest.
The development of new peptidic and non-peptidic
somatostatin analogues, subtype selective agonists, chimae-
ric analogues, or pan-somatostatin analogues will probably
improve the diagnosis and treatment of GEP NETs, which
express somatostatin receptors other than SSTR 2.
The combination of SSAs and IFN seems of benefit in
patients where the treatment with somatostatin analo-
gues alone failed to achieve a biochemical and sympto-
matic control while their synergistic effect on tumour
growth is still unknown.
The analysis of the SSTR status specifically for each
patient, and studies of individual tumour biological
behaviour, might be of therapeutic interest and could
help to optimise treatment expecially in unresectable
tumours.
Peptide-receptor-targeted radiotherapy for advanced
disease using radiolabeled octapeptide analogues appears
to be a significant progress in the treatment of GEP
NETs but data are limited, mainly about the best time
for its administration, or what is the most appropriate
radioligand/combination to be used for each patient,
and if and how the doses should be fractionated.
Novel strategies based on SSTR 2 receptor gene trans-
fer to target tumor growth and angiogenesis might offer
new prospectives of therapeutic interest mainly to treat
unresectable tumours.
Prospective studies including large number of patients
regarding the optimal dosage and modes of administra-
tion of somatostatin analogues and the development of
new slow release, SSTR subtype specific compounds are
needed.
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